NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-AG-24-023 from the NIH Guide for Grants and Contracts. The central goal of this funding initiative is to evaluate the molecular, pathologic and functional consequences of major toxicants known to be associated with elevated AD/ADRD risk, in mouse models of Late Onset AD (LOAD). Projects funded through this program will examine the consequences of early and mid-life exposure on late-life brain health by conducting cross-sectional/longitudinal multi-modal phenotyping (molecular, biochemical, pathologic and behavioral) of mouse models of LOAD, and the impact of genetic diversity and sex-differences on exposure-related AD outcomes.
Funding Opportunity RFA-AG-24-022 from the NIH Guide for Grants and Contracts. This funding opportunity announcement will support research focused on major toxicants observed to be associated with elevated AD risk, and health disparities in AD-related pathologic and clinical outcomes. This funding opportunity aims to enrich existing longitudinal cohorts with measures of exposures to individual toxicants or combinations of toxicants and/or multi-omics molecular profiling that reflects the bodys response to exposure(s), support the development of multi-disciplinary teams needed for the rigorous measurement and assessment of environmental exposures at the population level and create an environmental epidemiology consortium to facilitate rapid and broad data sharing, harmonization, and integration of complex exposure data across multiple studies to enhance the opportunity for data pooling and data integration for various meta-analyses and/or comparative analyses.
Funding Opportunity RFA-AG-24-021 from the NIH Guide for Grants and Contracts. The ?objective of this funding initiative is to stimulate research to gain mechanistic insights into gene-environment (GxE) interactions in response to environmental toxicants using human cell-based models. This RFA will support interdisciplinary research projects that utilize disease relevant human cell-based in vitro and ex vivo models to characterize the effects of gene environment interactions on gene regulation and cellular functions, and to elucidate toxicant mediated molecular and cellular mechanisms in brain aging and AD/ADRD.
Notice NOT-OD-23-131 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-23-032 from the NIH Guide for Grants and Contracts. The Funding Opportunity Announcement (FOA) solicits applications for the Bioinformatics Resource Center (BRC) Program that will (1) provide integrated knowledgebases to accelerate basic and applied human infectious diseases research, (2) develop advanced innovative bioinformatics technologies for software and tools, (3) offer state-of-the-art bioinformatics services for investigators in need and, (4) provide cutting-edge informatics support to the research community during public health emergencies.
Notice NOT-EY-23-007 from the NIH Guide for Grants and Contracts
Notice NOT-EY-23-006 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-23-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies.
Funding Opportunity RFA-NS-23-027 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-22-011 to comply with DMSP changes. No changes to receipt dates or locus of review. This funding opportunity announcement (FOA) is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. Proposed research should not represent a collection of individual efforts or parallel projects. This program is distinct from the NINDS P01 in that it will support a cohesive, single, well-integrated research plan with a singular focus, one set of aims, and a budget without subprojects. Teams are encouraged to consider transformative objectives with defined 5-year outcomes.
Funding Opportunity RFA-NS-24-010 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages early-stage development of novel small molecule or biologic therapeutics for NINDS mission-relevant? Alzheimer's and related dementias: frontotemporal degeneration (FTD, including Picks disease and progressive supranuclear palsy), Lewy body dementias (LBD; including dementia with Lewy bodies (DLB) and Parkinsons disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), and multiple etiology dementias (MED). This FOA covers four stages of early therapy discovery/development with each stage gated by go/no-go milestones. Applicants may enter the program at the stage appropriate to their research. The R61 phase supports preparatory research stages 1 -3: 1) development of in vitro and/or ex vivo assays that can support therapeutic screening efforts, 2) screening efforts to identify and characterize potential therapeutic agents, and 3) therapeutic optimization, pharmacodynamic and pharmacokinetic studies. The R33 phase supports stage 4, in vivo efficacy studies in an animal model of disease. This FOA supports research to enable competitive follow-on applications that meet the entry criteria for the Blueprint Neurotherapeutics Network, Blueprint Biologics, or other similar later-stage translational programs.
Funding Opportunity PAR-23-185 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.
Funding Opportunity PAR-23-186 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.
Funding Opportunity PAR-23-187 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.
Funding Opportunity PAR-23-188 from the NIH Guide for Grants and Contracts. The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.
Funding Opportunity RFA-DA-24-016 from the NIH Guide for Grants and Contracts. Only 1 in 10 people who need SUD treatment ever receive it. National survey data indicate that this treatment gap is largely driven by a misalignment between how treatment is designed (location, duration, structure, cost) and how patients prefer to engage in services. This FOA will support Patient Engagement Resource Centers to incorporate the perspectives of patients (including prospective patients, affected families, and persons in recovery) into research to inform the design and delivery of high quality treatment services that are responsive to their needs and preferences.
Notice NOT-MH-23-320 from the NIH Guide for Grants and Contracts
Notice NOT-HD-23-010 from the NIH Guide for Grants and Contracts
Notice NOT-HD-23-011 from the NIH Guide for Grants and Contracts
Notice NOT-DC-23-011 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-23-010 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to establish a clinical consortium to better understand the neurocognitive impact of new onset type 1 diabetes (T1D) in pre-pubertal children. Clinical Centers (CCs) will establish a diverse cohort of pre-pubertal children newly diagnosed with T1D and will evaluate disease-related perturbations in neurocognitive function, as well as identify potential clinical, developmental, and/or environmental factors associated with neurocognitive function in T1D.A separate NOFO (RFA-DK-23-009) will establish a Biostatistics Research Center (BRC) to oversee the development and coordination of a core protocol to be adopted by each CC awarded under the current NOFO (RFA-DK-23-010). The PI(s) of the BRC and the PIs from each of the CCs selected via RFA-DK-23-010 will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol across approximately 10 CCs and the BRC.Findings from this observational study are expected to advance our understanding of the impact of T1D on the developing brain and identify risk and protective factors associated with neurocognitive functioning to ultimately inform on effective strategies to decrease adverse neurodevelopmental outcomes and long-term neurocognitive sequelae of T1D.